Program
venetoclax
Also written as “Venetoclax”, “ABT-199” and “ABT-199 (Main Cohort)”.
Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 3 companies.
Drug pageVenetoclax: every studyAll 486 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 5312 open or running | phase 4since Nov 22, 2021 | Apr 1, 2011 | Nov 2026phase 2 · NCT04895436 |
| Hoffmann-La Roche | 131 open or running | phase 3since Dec 4, 2013 | Aug 10, 2012 | none ahead |
| Oncotherapeuticsits history only | 11 open or running | phase 2since Aug 11, 2023 | Aug 11, 2023 | none ahead |
Also a collaborator on its studies: Johnson & Johnson, Baili-Bio (Chengdu) Pharmaceutical, Roche-Genentech, Merck, Sumitomo Pharma and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 10, 2012First study: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT01671904 · 84 enrolled · United States, France, Germany
- Sep 12, 2012Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellNCT01685892 · 82 enrolled · United States, United Kingdom
- Dec 4, 2013Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02005471 · 389 enrolled · United States, Australia, Austria and more
- Feb 4, 2014Phase 2 study in Lymphoma, Non-HodgkinNCT02055820 · 267 enrolled · United States, Australia, Austria and more
- Jul 9, 2014Phase 2 study in Lymphoma, FollicularNCT02187861 · 163 enrolled · United States, Australia, Belgium and more
- Sep 16, 2014Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02242942 · 445 enrolled · United States, Argentina, Australia and more
- Oct 12, 2017Phase 2 study in Multiple MyelomaNCT03312530 · 49 enrolled · Czechia, Denmark, France and more
- Jun 25, 2018Phase 2 study in Breast NeoplasmsNCT03584009 · 103 enrolled · United States, Australia, Canada and more
- Feb 25, 2020Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04285567 · 166 enrolled · United States, Australia, France and more
- Mar 5, 2020Phase 2 study in Breast NeoplasmsNCT04298918 · 1 enrolled · Australia, Korea, Republic of
- Jun 5, 2020Phase 1 study in Small Cell Lung CarcinomaNCT04422210 · 2 enrolled · United States, Denmark, Korea, Republic of and more
- Mar 8, 2021Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT04790903 · 50 enrolled · United States, France, Italy and more
- Jul 23, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06524375 · 118 enrolled · United States
TargetBeta
“Apoptosis regulator Bcl-2 inhibitor”ChEMBL 37, by rule
Other programs on BCL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bcl-2 Inhibitor TQB3909 | Sino Biopharmaceutical | phase 3 | 8 |
| lacutoclaxrule | Lupeng Pharmaceutical | phase 2 | 4 |
| surzetoclax | AbbVie | phase 2 | 3 |
| 400mg of TQB3909 tablets | Sino Biopharmaceutical | phase 2 | 1 |
| surzetoclax | AbbVie | phase 1 | 2 |
| FXS0683 | Fosun Pharma | phase 1 | 1 |
Studies
All 13 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06524375Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Active, not recruiting | Oct 28, 2026 | 118 |
| NCT04790903Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more | 1 | Terminated | May 21, 2024 | 50 |
| NCT04422210Small Cell Lung Carcinoma · United States, Denmark, Korea, Republic of and more | 1 | Terminated | Nov 6, 2020 | 2 |
| NCT04298918Breast Neoplasms · Australia, Korea, Republic of | 2 | Terminated | Feb 4, 2021 | 1 |
| NCT04285567Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 3 | Completed | Mar 19, 2024 | 166 |
| NCT03584009Breast Neoplasms · United States, Australia, Canada and more | 2 | Terminated | Aug 5, 2020 | 103 |
| NCT03312530Multiple Myeloma · Czechia, Denmark, France and more | 2 | Completed | May 18, 2021 | 49 |
| NCT02242942Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Completed | Aug 17, 2018 | 445 |
| NCT02187861Lymphoma, Follicular · United States, Australia, Belgium and more | 2 | Completed | Sep 27, 2016 | 163 |
| NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more | 2 | Completed | Jun 28, 2017 | 267 |
| NCT02005471Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | May 8, 2017 | 389 |
| NCT01685892Leukemia, Lymphocytic, Chronic, B-Cell · United States, United Kingdom | 1 | Completed | May 21, 2018 | 82 |
| NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany | 1 | Completed | Aug 17, 2018 | 84 |
How it is read
Names in the registry
- “Venetoclax”, 66 entries
- “ABT-199”, 9 entries
- “venetoclax”, 6 entries
- “ABT-199 (Main Cohort)”, 1 entry
- “ABT-199 (Safety Expansion Cohort)”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 21 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 21 studies
- Multiple Myeloma, 10 studies
- Lymphoma, Non-Hodgkin, 7 studies
- Lymphoma, Mantle-Cell, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.